H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Interpace Diagnostics Group Inc (IDXG) on March 20 and set a price target of $3.50. The company’s shares closed on Friday at $0.85, close to its 52-week low of $0.76.
Selvaraju said:
“Our 12-month price target is derived from an estimated market value of the firm at $130M. This includes a discounted cash flow analysis based asset value for the company’s three commercialized laboratory-developed tests (LDTs), with a 15% discount rate and a 2% terminal growth rate, and assuming 38.6M shares outstanding at the end of 2019.”
According to TipRanks.com, Selvaraju is currently ranked with no stars on a 0-5 star ranking scale, with an average return of -5.6% and a 29.6% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Biospecifics Technologies Corp, EyePoint Pharmaceuticals Inc, and Bausch Health Companies Inc.
Currently, the analyst consensus on Interpace Diagnostics Group Inc is a Moderate Buy with an average price target of $3.75, which is a 342.1% upside from current levels. In a report issued on March 20, Maxim Group also maintained a Buy rating on the stock with a $4 price target.
See today’s analyst top recommended stocks >>
Based on Interpace Diagnostics Group Inc’s latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $4.04 million. In comparison, last year the company had a GAAP net loss of $5.01 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Interpace Diagnostics Group, Inc. operates as an bioinformatics company, which engages in the development and commercialization of molecular diagnostic test and pathology services. It offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion molecular test that can aid in pancreatic cyst diagnosis and pancreatic cancer risk assessment; ThyGenX and PathFinderTG which assesses thyroid nodules for risk of malignancy; and ThyraMIR, which assesses thyroid nodules for risk of malignancy utilizing a proprietary gene expression assay. The company was founded by John P. Dugan in 1987 and is headquartered in Parsippany, NJ.
